Reduced-Dose Anticoagulants Feasible for Extended VTE Tx

May be as effective as full-dose direct oral anticoagulants for extended-duration treatment

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

TUESDAY, May 29, 2018 (HealthDay News) -- For an extended duration, reduced-dose direct oral anticoagulants (DOACs) may be as effective as full-dose treatment for preventing recurrent venous thromboembolism (VTE), according to a review published online May 17 in the Journal of Thrombosis and Haemostasis.

Lakshman Vasanthamohan, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted a systematic literature review to identify studies comparing reduced-dose DOACs with full-dose DOACs and aspirin or placebo in the extended phase of VTE treatment.

The researchers found that two trials met pre-specified inclusion criteria (5,847 patients for efficacy outcomes and 5,842 patients for safety outcomes). For preventing recurrent VTE at one year, reduced-dose DOACs were as effective as full-dose treatment (relative risk [RR], 1.12; 95 percent confidence interval [CI], 0.67 to 1.87) and more effective than aspirin or placebo (RR, 0.26; 95 percent CI, 0.14 to 0.46). For reduced-dose DOACs and aspirin or placebo, the risk of major or clinically relevant non-major bleeding events was similar (RR, 1.19; 95 percent CI, 0.81 to 1.77). For reduced- versus full-dose DOACs, there was a trend toward less bleeding (RR, 0.74; 95 percent CI, 0.52 to 1.05).

"Extended-duration treatment of VTE with reduced-dose DOAC may be as efficacious as full-dose treatment, with rates of major bleeding similar to treatment with aspirin or placebo, but further long-term studies are needed," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Last Updated: